Igor Gitelman

Interim Chief Financial Officer at Ayala Pharmaceuticals

Mr. Gitelman has served as Advaxis's Interim Chief Financial Officer since May of 2022, VP of Finance since November 2020, and Chief Accounting Officer since February 2021. Before joining Advaxis, Mr. Gitelman served as CFO Executive Financial Consultant for Accu Reference Medical Labs, a clinical diagnostic laboratory. Before that, from February 2017 through November 2018, Mr. Gitelman served as a chief accounting officer of Cancer Genetics, Inc., a drug discovery, preclinical oncology, and immuno-oncology services company. Prior to that, Mr. Gitelman served as an Assistant to the Vice President (AVP) of Finance and Tax at the clinical diagnostic laboratory, BioReference Laboratories, Inc., from October 2005 to October 2016. During this time at BioReference Laboratories, Inc., Mr. Gitelman held various positions of increasing responsibility for managing the company’s internal audit function, SEC financial reporting, tax, and corporate finance functions.

Timeline

  • Interim Chief Financial Officer

    Current role

View in org chart